Claims for Patent: 9,657,104

Summary for Patent: 9,657,104

Title:	Anti-c-Met/anti-EGFR bispecific antibodies
Abstract:	There are provided an anti-c-Met/anti-EGFR bispecific antibody, a method for treating cancer using the same, and an anti-EGFR scFv fragment.
Inventor(s):	Cho; Mi Young (Seoul, KR), Lee; Seung Hyun (Suwon-si, KR), Cheong; Kwang Ho (Seoul, KR), Lin; Powei (Hwaseong-si, KR), Hwang; Jae Woong (Seoul, KR), Yi; Christina (Seongnam-si, KR), Koh; Young Jun (Yongin-si, KR)
Assignee:	SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)
Application Number:	14/231,376
Patent Claims:	1. An anti-c-Met/anti-EGFR bispecific antibody comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof and (b) an anti-EGFR antibody or an antigen-binding fragment thereof, wherein the anti-c-Met antibody or the antigen-binding fragment thereof comprises: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3, (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10, (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11, and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 37. 2. The anti-c-Met/anti-EGFR bispecific antibody according to claim 1, wherein the antigen-binding fragment is scFv, (scFv)2, scFvFc, Fab, Fab' or F(ab').sub.2. 3. The anti-c-Met/anti-EGFR bispecific antibody according to claim 1, wherein the anti-c-Met antibody or the antigen-binding fragment thereof comprises: (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 62, the amino acid sequence from the 18.sup.th to 462.sup.nd positions of the amino acid sequence of SEQ ID NO: 62, the amino acid sequence of SEQ ID NO: 64, the amino acid sequence from the 18.sup.th to 461.sup.st positions of the amino acid sequence of SEQ ID NO: 64, the amino acid sequence of SEQ ID NO: 66, or the amino acid sequence from the 18.sup.th to 460.sup.th positions of the amino acid sequence of SEQ ID NO: 66; and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 68, the amino acid sequence from the 21.sup.st to 240.sup.th positions of the amino acid sequence of SEQ ID NO: 68, the amino acid sequence of SEQ ID NO: 70, or the amino acid sequence from the 21.sup.st to 240.sup.th positions of the amino acid sequence of SEQ ID NO: 70. 4. The anti-c-Met/anti-EGFR bispecific antibody according to claim 1, wherein the antigen-binding fragment of the anti-EGFR antibody is: (a) an antigen binding fragment of Cetuximab, (b) an antigen binding fragment of Panitumumab, or (c) an antigen binding fragment comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 109 or SEQ ID NO: 113, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 111 or SEQ ID NO: 114. 5. The anti-c-Met/anti-EGFR bispecific antibody according to claim 1, comprising an anti-c-Met antibody and an antigen-binding fragment of an anti-EGFR antibody, wherein the antigen-binding fragment of the anti-EGFR antibody is coupled to the C terminus of the anti-c-Met antibody. 6. A method of treatment of a cancer, comprising administering the anti-c-Met/anti-EGFR bispecific antibody of claim 1 to a patient in need thereof. 7. The method according to claim 6, wherein the antigen-binding fragment is scFv, (scFv)2, scFvFc, Fab, Fab' or F(ab').sub.2 of the antibody. 8. The method according to claim 6, wherein the antigen-binding fragment of the anti-EGFR antibody is (a) an antigen binding fragment of Cetuximab, (b) an antigen binding fragment of Panitumumab, or (c) an antigen binding fragment comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 109 or SEQ ID NO: 113, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 111 or SEQ ID NO: 114. 9. The method according to claim 6, wherein the anti-c-Met/anti-EGFR bispecific antibody comprises an anti-c-Met antibody and an antigen-binding fragment of an anti-EGFR antibody, wherein the antigen-binding fragment of the anti-EGFR antibody is coupled to the C terminus of the anti-c-Met antibody.

Details for Patent 9,657,104

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2033-03-29
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2033-03-29
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2033-03-29